Reporting owner · Q3 2026 · CIK 1682093

OrbiMed Advisors Israel II Ltd: insider trades.

OrbiMed Advisors Israel II Ltd reported 11 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 3 open-market purchases ($16.1M) and 0 sales, across 1 company.

Transactions
11
Purchases (P)
3
Sales (S)
0
Companies
1
Name as filed
OrbiMed Advisors Israel II Ltd

Companies

CompanyRelationshipTransactions
ADARx Pharmaceuticals, Inc. (ADRX)Director, TenPercentOwner11

Transactions

11 non-derivative rows. Shares and prices as filed.
DateCompanyCodeSharesPriceOwned afterFiling
2026-09-28ADARx Pharmaceuticals, Inc.C564,187—14,025,280Form 4
2026-09-28ADARx Pharmaceuticals, Inc.P300,249$1714,325,529Form 4
2026-09-28ADARx Pharmaceuticals, Inc.C7,127,019—7,127,019Form 4
2026-09-28ADARx Pharmaceuticals, Inc.C1,333,975—8,460,994Form 4
2026-09-28ADARx Pharmaceuticals, Inc.C513,067—8,974,061Form 4
2026-09-28ADARx Pharmaceuticals, Inc.C256,448—9,230,509Form 4
2026-09-28ADARx Pharmaceuticals, Inc.C769,601—13,461,093Form 4
2026-09-28ADARx Pharmaceuticals, Inc.C2,000,962—12,691,492Form 4
2026-09-28ADARx Pharmaceuticals, Inc.C10,690,530—10,690,530Form 4
2026-09-28ADARx Pharmaceuticals, Inc.P61,516$179,292,025Form 4
2026-09-28ADARx Pharmaceuticals, Inc.P588,235$17588,235Form 4

Questions

What stock did OrbiMed Advisors Israel II Ltd buy or sell?

OrbiMed Advisors Israel II Ltd reported 11 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 3 open-market purchases ($16.1M) and 0 sales, across 1 company.

Is OrbiMed Advisors Israel II Ltd the same person as other filers with this name?

This page covers SEC CIK 1682093 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.

Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.

Plain-text version for agents and LLMs: /insiders/orbimed-advisors-israel-ii-ltd-1682093.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.